首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations.
【24h】

Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations.

机译:在澳大利亚和新西兰的腹膜透析患者人群中,腹膜的小溶质清除率与患者的存活率呈非线性关系。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The contribution of peritoneal small solute clearance per se to peritoneal dialysis (PD) patient outcomes remains uncertain. The aim of the present study was to determine whether baseline peritoneal small solute clearance predicted subsequent survival in Australian and New Zealand PD patients. METHODS: The study included all adult patients in Australia and New Zealand that commenced PD between 1 April 2002 and 31 December 2005 and had a peritoneal Kt/V (pKt/V) measurement performed within 6 months of PD commencement. Time to death and death-censored technique failure were examined by Kaplan-Meier analyses and both univariate and multivariate Cox proportional hazards models. RESULTS: pKt/V measurements were available in 2434 (63%) of the 3841 individuals that began PD treatment in Australia and New Zealand during the study period. These patients were divided into 4 groups according to their baseline pKt/V values: <1.45 (n = 599), 1.45 - 1.69 (n = 550), 1.70 - 2.00 (n = 607), and >2.00 (n = 678). Compared with the reference group (pKt/V 1.70 - 2.00), patient mortality was significantly increased in individuals with pKt/V <1.45 [adjusted hazard ratio (HR) 1.87, 95% confidence interval (CI) 1.24 - 2.84; p = 0.003] and tended to be increased in those with pKt/V 1.45 - 1.69 (adjusted HR 1.46, 95% CI 0.96 - 2.21; p = 0.074). Importantly, higher pKt/V values (>2.00) also tended to be associated with higher mortality (adjusted HR 1.42, 95% CI 0.96 - 2.11; p = 0.079). The other independent predictors of death were lower residual renal function (RRF), older age, peripheral vascular disease, diabetes mellitus, late referral, higher peritoneal permeability, and untreated hypertension. No interaction was observed between pKt/V, RRF, and survival. Death-censored technique failure was demonstrated to be significantly worse in the pKt/V 1.45 - 1.69 group (adjusted HR 1.36, 95% CI 1.03 - 1.79; p = 0.028), older individuals, and individuals with Asian racial origin. CONCLUSIONS: Initial peritoneal Kt/V significantly and independently influences patient survival in Australian and New Zealand PD patients. Overall survival appears to be optimal in the pKt/V range 1.70 - 2.00, with poorer outcomes observed above and below these values. In particular, survival is significantly worse when the achieved pKt/V is <1.45. In addition, RRF is an important independent predictor of patient survival in the Australian and New Zealand incident PD patient populations. The results of this study should therefore draw attention to the possible danger of not delivering adequate PD dose to patients with considerable RRF.
机译:背景:腹膜小的溶质清除本身对腹膜透析(PD)患者预后的贡献仍然不确定。本研究的目的是确定基线腹膜小溶质清除率是否可预测澳大利亚和新西兰PD患者的后续生存。方法:该研究纳入了澳大利亚和新西兰的所有成人患者,这些患者在2002年4月1日至2005年12月31日期间开始PD,并在PD开始6个月内进行了腹膜Kt / V(pKt / V)测量。通过Kaplan-Meier分析以及​​单变量和多变量Cox比例风险模型检查了死亡时间和以死亡检查的技术失败。结果:在研究期间,在澳大利亚和新西兰开始进行PD治疗的3841名个体中,有2434名(63%)进行了pKt / V测量。根据基线pKt / V值将这些患者分为4组:<1.45(n = 599),1.45-1.69(n = 550),1.70-2.00(n = 607)和> 2.00(n = 678) 。与参考组相比(pKt / V 1.70-2.00),pKt / V <1.45的患者的死亡率显着增加[调整后的危险比(HR)1.87,95%置信区间(CI)1.24-2.84; p = 0.003],并且在pKt / V为1.45-1.69的人群中有升高的趋势(调整后的HR 1.46,95%CI 0.96-2.21; p = 0.074)。重要的是,较高的pKt / V值(> 2.00)也往往与较高的死亡率相关(校正后的HR 1.42,95%CI 0.96-2.11; p = 0.079)。死亡的其他独立预测因素是较低的残余肾功能(RRF),年龄较大,外周血管疾病,糖尿病,转诊晚,腹膜通透性较高和未治疗的高血压。在pKt / V,RRF和存活之间未观察到相互作用。在pKt / V 1.45-1.69组(校正后的HR 1.36,95%CI 1.03-1.79; p = 0.028),年龄较大的个体以及具有亚洲种族血统的个体中,以死亡为前提的技术失败被证明更为严重。结论:初始腹膜Kt / V显着独立地影响澳大利亚和新西兰PD患者的生存。在1.70-2.00的pKt / V范围内,总体存活率似乎是最佳的,在这些值的上方和下方观察到较差的结果。尤其是,当达到的pKt / V <1.45时,生存率将大大降低。此外,RRF是澳大利亚和新西兰突发PD患者人群中患者生存的重要独立预测指标。因此,这项研究的结果应引起人们的注意,即可能不会对具有相当大的RRF的患者提供足够的PD剂量的危险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号